Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways

Liver fibrosis

Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958 · see citing works

Phosphorylation meets ubiquitination: the control of NF-κB activity

Karin, M., & Ben-Neriah, Y. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.621 · Cited by 4,766 · see citing works

Missing Pieces in the NF-κB Puzzle

Ghosh, S., & Karin, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00703-1 · Cited by 3,638 · see citing works

Mechanisms of Hepatic Fibrogenesis

Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,640 · see citing works

FGF-21 as a novel metabolic regulator

Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125 · see citing works

Liver fibrosis – from bench to bedside

Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780 · see citing works

The Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment Strategies

Flier, J. S., Underhill, L. H., & Friedman, S. L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306243282508 · Cited by 1,433 · see citing works

NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma

Luedde, T., & Schwabe, R. F. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.213 · Cited by 1,345 · see citing works

Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice

Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151 · see citing works

Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors

Iredale, J. P., Benyon, R. C., Pickering, J., McCullen, M., Northrop, M., Pawley, S., Hovell, C., & Arthur, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1018 · Cited by 1,075 · see citing works

Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF‐β

Yang, X. Y., Letterio, J. J., Lechleider, R. J., Chen, L., Hayman, R., Gu, H., Roberts, A. B., & Deng, C. (1999) · The EMBO Journal · doi:10.1093/emboj/18.5.1280 · Cited by 889 · see citing works

Roles of TGF-beta in hepatic fibrosis

Gressner, A. M. (2002) · Frontiers in bioscience · doi:10.2741/a812 · Cited by 785 · see citing works

The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21

Kharitonenkov, A., Wroblewski, V. J., Koester, A., Chen, Y.-F., Clutinger, C. K., Tigno, X. T., Hansen, B. C., Shanafelt, A. B., & Etgen, G. J. (2007) · Endocrinology · doi:10.1210/en.2006-1168 · Cited by 738 · see citing works

Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease

Itoh, N., & Ornitz, D. M. (2010) · The Journal of Biochemistry · doi:10.1093/jb/mvq121 · Cited by 708 · see citing works

FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response

Potthoff, M. J., Inagaki, T., Satapati, S., Ding, X., He, T., Goetz, R., Mohammadi, M., Finck, B. N., Mangelsdorf, D. J., Kliewer, S. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904187106 · Cited by 704 · see citing works

Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease

Dushay, J., Chui, P. C., Gopalakrishnan, G. S., Varela–Rey, M., Crawley, M., Fisher, F. M., Badman, M. K., Martinez–Chantar, M. L., & Maratos–Flier, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.054 · Cited by 607 · see citing works

Evolving therapies for liver fibrosis

Schuppan, D., & Kim, Y. O. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66028 · Cited by 596 · see citing works

Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats

Wright, M. C., Issa, R., Smart, D. E., Trim, N., Murray, G. I., Primrose, J. M., Arthur, M. J. P., Iredale, J. P., & Mann, D. A. (2001) · Gastroenterology · doi:10.1053/gast.2001.27188 · Cited by 356 · see citing works

Toll-like receptors as targets in chronic liver diseases

Mencin, A. M., Kluwe, J., & Schwabe, R. F. (2009) · Gut · doi:10.1136/gut.2008.156307 · Cited by 328 · see citing works

Molecular mechanisms of hepatic fibrogenesis

Parsons, C. J., Takashima, M., & Rippe, R. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04659.x · Cited by 323 · see citing works

Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation

Carpino, G., Morini, S., Corradini, S. G., Franchitto, A., Merli, M., Siciliano, M., Gentili, F., Muda, A. O., Berloco, P. B., & Rossi, M. (2005) · Digestive and Liver Disease · doi:10.1016/j.dld.2004.11.009 · Cited by 310 · see citing works

Blockade of type β transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat

Qi, Z., Atsuchi, N., Ooshima, A., Takeshita, A., & Ueno, H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2345 · Cited by 288 · see citing works

Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice.

Clouthier, D. E., Comerford, S. A., & Hammer, R. E. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119815 · Cited by 282 · see citing works

Inhibition of inhibitor of κB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis

Oakley, F., Meso, M., Iredale, J. P., Green, K., Marek, C. J., Zhou, X., May, M. J., Millward‐Sadler, H., Wright, M. C., & Mann, D. A. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.10.003 · Cited by 265 · see citing works

Signal transduction in hepatic stellate cells

Pinzani, M., Marra, F., & Carloni, V. (1998) · Liver International · doi:10.1111/j.1600-0676.1998.tb00120.x · Cited by 232 · see citing works

New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis

Wang, Y., Gao, J., Zhang, D., Zhang, J., Ma, J., & Jiang, H. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.02.027 · Cited by 232 · see citing works

Amelioration of Radiation-induced Fibrosis

Xavier, S., Piek, E., Fujii, M., Javelaud, D., Mauviel, A., Flanders, K., Samuni, A. M., Felici, A., Reiß, M., Yarkoni, S., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309798200 · Cited by 191 · see citing works

Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1α-mediated antioxidant capacity in mice

Ye, D., Wang, Y., Li, H., Jia, W., Man, K., Lo, C. M., Wang, Y., Lam, K. S. L., & Xu, A. (2014) · Hepatology · doi:10.1002/hep.27060 · Cited by 184 · see citing works

Inhibition of NFκB in activated rat hepatic stellate cells by proteasome inhibitors and an IκB super-repressor

Hellerbrand, C., Jobin, C., Iimuro, Y., Licato, L. L., Sartor, R. B., & Brenner, D. A. (1998) · Hepatology · doi:10.1002/hep.510270514 · Cited by 170 · see citing works

Myofibroblast – like cells and liver fibrogenesis: Emerging concepts in a rapidly moving scenario

Parola, M., Marra, F., & Pinzani, M. (2007) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2007.09.002 · Cited by 169 · see citing works

NF-κB, an Evolutionarily Conserved Mediator of Immune and Inflammatory Responses

Xiao, C., & Ghosh, S. (2005) · Advances in Experimental Medicine and Biology · doi:10.1007/0-387-24180-9_5 · Cited by 167 · see citing works

Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans

Novo, E., Marra, F., Zamara, E., di Bonzo, L. V., Monitillo, L., Cannito, S., Petrai, I., Mazzocca, A., Bonacchi, A., Franco, R. S. M. D., et al. (2006) · Gut · doi:10.1136/gut.2005.082701 · Cited by 167 · see citing works

Fibroblast Growth Factor 21 (FGF-21) and Its Relation to Obesity, Metabolic Syndrome, and Nonalcoholic Fatty Liver in Children: A Longitudinal Analysis

Reinehr, T., Woelfle, J., Wunsch, R., & Roth, C. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1221 · Cited by 160 · see citing works

Adenosine signaling contributes to ethanol-induced fatty liver in mice

Peng, Z., Borea, P. A., Wilder, T., Yee, H. T., Chiriboga, L. A., Blackburn, M. R., Azzena, G., Resta, G., & Cronstein, B. N. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37409 · Cited by 160 · see citing works

Chemokines in Liver Inflammation and Fibrosis

Wasmuth, H. E., Tacke, F., & Trautwein, C. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255351 · Cited by 159 · see citing works

Modulation of transforming growth factor beta receptors of rat lipocytes during the hepatic wound healing response. Enhanced binding and reduced gene expression accompany cellular activation in culture and in vivo.

Friedman, S. L., Yamasaki, G., & Wong, L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34095-4 · Cited by 152 · see citing works

Stellate cells and the development of liver cancer: Therapeutic potential of targeting the stroma

Coulouarn, C., & Clément, B. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.02.003 · Cited by 142 · see citing works

Gliotoxin-mediated apoptosis of activated human hepatic stellate cells

Kweon, Y.-O., Paik, Y., Schnabl, B., Qian, T., Lemasters, J. J., & Brenner, D. A. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00178-8 · Cited by 140 · see citing works

Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats

Kaji, K., Yoshiji, H., Ikenaka, Y., Noguchi, R., Aihara, Y., Douhara, A., Moriya, K., Kawaratani, H., Shirai, Y., Yoshii, J., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0783-4 · Cited by 133 · see citing works

TGF-β/Smad signaling during hepatic fibro-carcinogenesis (Review)

Yoshida, K., MURATA, M., Yamaguchi, T., & Matsuzaki, K. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2552 · Cited by 130 · see citing works

Angiotensin II Activates IκB Kinase Phosphorylation of RelA at Ser536 to Promote Myofibroblast Survival and Liver Fibrosis

Oakley, F., Teoh, V. W. Y., Ching-A-Sue, G., Bataller, R. A., Colmenero, J., Jonsson, J. R., Eliopoulos, A. G., Watson, M. R., Manas, D., & Mann, D. A. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.081 · Cited by 127 · see citing works

Hepatic Fibrogenesis

Guo, J., & Friedman, S. L. (2007) · Seminars in Liver Disease · doi:10.1055/s-2007-991517 · Cited by 115 · see citing works

Fibroblast growth factor (FGF21) protects mouse liver against d-galactose-induced oxidative stress and apoptosis via activating Nrf2 and PI3K/Akt pathways

Yu, Y.-H., Bai, F., Liu, Y., Yang, Y., Yuan, Q., Zou, D., Qu, S., Tian, G., Song, L., Zhang, T., et al. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2358-6 · Cited by 108 · see citing works

Distinct Changes in Serum Fibroblast Growth Factor 21 Levels in Different Subtypes of Diabetes

Xiao, Y., Xu, A., Law, L. S., Chen, C., Li, H., Li, X., Yang, L., Liu, S., Zhou, Z., & Lam, K. S. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1930 · Cited by 102 · see citing works

Inhibition of liver fibrosis by solubilized coenzyme Q10: Role of Nrf2 activation in inhibiting transforming growth factor-β1 expression

Choi, H., Pokharel, Y. R., Lim, S., Han, H.-K., Ryu, C. S., Kim, S. K., Kwak, M. K., & Kang, K. W. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.07.030 · Cited by 98 · see citing works

Serum FGF 21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status

Lee, Y., Lim, S. K., Hong, E. S., Kim, J. H., Moon, M. K., Chun, E. J., Choi, S. I., Kim, Y., Park, Y. J., Park, K. S., et al. (2012) · Clinical Endocrinology · doi:10.1111/cen.12134 · Cited by 84 · see citing works

TGFβ1 in liver fibrosis: time to change paradigms?

Bauer, M. W., & Schuppan, D. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02655-2 · Cited by 84 · see citing works

Butein inhibits ethanol-induced activation of liver stellate cells through TGF-β, NFκB, p38, and JNK signaling pathways and inhibition of oxidative stress

Szuster‐Ciesielska, A., Mizerska-Kowalska, M., Daniluk, J., & Kandefer‐Szerszeń, M. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0619-7 · Cited by 75 · see citing works

Molecular characteristics of dimethylnitrosamine induced fibrotic liver collagen

George, J., & Chandrakasan, G. (1996) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/0167-4838(95)00202-2 · Cited by 73 · see citing works

The use of low molecular weight heparin–pluronic nanogels to impede liver fibrosis by inhibition the TGF-β/Smad signaling pathway

Lee, J., Lee, H., Joung, Y. K., Jung, K. H., Choi, J.-H., Lee, D., Park, K. D., & Hong, S. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.10.023 · Cited by 70 · see citing works

Semiquantitative evaluation of hepatic fibrosis by measuring tissue hydroxyproline.

Toyoki, Y., Sasaki, M., Narumi, S., Yoshihara, S., Morita, T., & Mituru, K. O. N. N. (1998) · PubMed · Cited by 36 · see citing works

Tissue remodeling following submassive hemorrhagic necrosis in rat livers induced by an intraperitoneal injection of dimethylnitrosamine

Jin, Y., Enzan, H., Kuroda, N., Hayashi, Y., Nakayama, H., Zhang, Y.-H., Toi, M., Miyazaki, E., Hiroi, M., Guo, L., et al. (2003) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-002-0703-0 · Cited by 29 · see citing works

Elucidation of the role of COX-2 in liver fibrogenesis using transgenic mice

Yu, J. Q., Wu, C. W., Chu, E. S., Hui, A., Cheng, A. S. L., Go, M. Y. Y., Ching, A. K.-K., Chui, Y., Chan, H. L., & Sung, J. J. �. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.05.069 · Cited by 27 · see citing works

Evaluation of intracellular signalling pathways in response to insulin-like growth factor I in apoptotic-resistant activated human hepatic stellate cells

Gentilini, A., Lottini, B., Brogi, M., Caligiuri, A., Cosmi, L., Marra, F., & Pinzani, M. (2009) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-2-1 · Cited by 24 · see citing works

Stephania tetrandra prevents and regresses liver fibrosis induced by carbon tetrachloride in rats

Chor, J. S. Y., Yu, J. Q., Chan, K. K., Go, Y. Y., & Sung, J. J. �. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05720.x · Cited by 14 · see citing works

The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic

Geng, L., Lam, K. S. L., & Xu, A. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0386-0 · Cited by 607 · see citing works

Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease

Targher, G., & Byrne, C. D. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.16 · Cited by 313 · see citing works

Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy

Tan, Z., Sun, H., Xue, T., Gan, C., Liu, H., Xie, Y., Yao, Y., & Ye, T. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.730176 · Cited by 220 · see citing works

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases

Tillman, E. J., & Rolph, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601290 · Cited by 209 · see citing works

Pathogenesis and novel treatment options for non-alcoholic steatohepatitis

Wong, V. W., Chitturi, S., Wong, G. L., Yu, J. Q., Chan, H. L., & Farrell, G. C. (2016) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30011-5 · Cited by 186 · see citing works

Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)

Do, A., Zahrawi, F. M., & Mehal, W. Z. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01084-2 · Cited by 188 · see citing works

FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond

Harrison, S. A., Rolph, T., Knott, M., & Dubourg, J. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.034 · Cited by 176 · see citing works

Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities

Musso, G., Cassader, M., Cohney, S. J., Michieli, F. D., Pinach, S., Saba, F., & Gambino, R. (2016) · Diabetes Care · doi:10.2337/dc15-1182 · Cited by 162 · see citing works

Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)

Wang, S., & Friedman, S. L. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0759 · Cited by 158 · see citing works

Fibroblast growth factor 21 in non-alcoholic fatty liver disease

Tucker, B., Li, H., Long, X., Rye, K., & Ong, K. L. (2019) · Metabolism · doi:10.1016/j.metabol.2019.153994 · Cited by 132 · see citing works

Regulation of longevity by FGF21: interaction between energy metabolism and stress responses

Salminen, A., Kaarniranta, K., & Kauppinen, A. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.05.004 · Cited by 121 · see citing works

FGF21 attenuates neurodegeneration through modulating neuroinflammation and oxidant-stress

Kang, K., Xu, P., Wang, M., Chunyu, J., Sun, X., Ren, G., Xiao, W. L., & Li, D. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110439 · Cited by 117 · see citing works

FGF21 activates AMPK signaling: impact on metabolic regulation and the aging process

Salminen, A., Kauppinen, A., & Kaarniranta, K. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1477-1 · Cited by 117 · see citing works

A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis

Harrison, S. A., Ruane, P. J., Freilich, B., Neff, G., Patil, R., Behling, C., Hu, C., Shringarpure, R., de Temple, B., Fong, E., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2022.100563 · Cited by 110 · see citing works

Schisandrin B attenuates CCl4-induced liver fibrosis in rats by regulation of Nrf2-ARE and TGF-β/Smad signaling pathways

Chen, Q., Zhang, H., Cao, Y. W., Li, Y., Sun, S., Zhang, J., & Zhang, G. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s137507 · Cited by 106 · see citing works

FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases

Sonoda, J., Chen, M. Z., & Baruch, A. (2017) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0002 · Cited by 106 · see citing works

FGF19 and FGF21 for the Treatment of NASH—Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human

Henriksson, E., & Andersen, B. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601349 · Cited by 95 · see citing works

Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis

Zarei, M., Pizarro‐Delgado, J., Barroso, E., Palomer, X., & Vázquez‐Carrera, M. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.12.005 · Cited by 92 · see citing works

FGF19 and FGF21: In NASH we trust

Talukdar, S., & Kharitonenkov, A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101152 · Cited by 82 · see citing works

Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches

Kim, K. H., & Lee, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00485 · Cited by 77 · see citing works

Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities

Manka, P. P., Zeller, A. C., & Syn, W. (2019) · Drugs · doi:10.1007/s40265-019-01126-9 · Cited by 77 · see citing works

Fibroblast growth factor-based pharmacotherapies for the treatment of obesity-related metabolic complications

Jin, L., Yang, R., Geng, L., & Xu, A. (2023) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032322-093904 · Cited by 71 · see citing works

Regulation of Hepatic Stellate Cells and Fibrogenesis by Fibroblast Growth Factors

Schumacher, J. D., & Guo, G. L. (2016) · BioMed Research International · doi:10.1155/2016/8323747 · Cited by 70 · see citing works

FGF21 augments autophagy in random-pattern skin flaps via AMPK signaling pathways and improves tissue survival

Zhou, K., Chen, H. A., Lin, J., Xu, H., Wu, H., Bao, G., Li, J., Deng, X., Shui, X., Gao, W., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2105-0 · Cited by 67 · see citing works

Role of fibroblast growth factor signalling in hepatic fibrosis

Seitz, T., & Hellerbrand, C. (2021) · Liver International · doi:10.1111/liv.14863 · Cited by 64 · see citing works

FGF21 attenuates pulmonary fibrogenesis through ameliorating oxidative stress in vivo and in vitro

Zhang, S., Yu, D., Wang, M., Huang, T., Wu, H., Zhang, Y., Zhang, T., Wang, W., Yin, J., Ren, G., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.03.100 · Cited by 62 · see citing works

Therapeutic pro-fibrogenic signaling pathways in fibroblasts

Cannito, S., Novo, E., & Parola, M. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.017 · Cited by 60 · see citing works

Fibroblast growth factor 18 stimulates the proliferation of hepatic stellate cells, thereby inducing liver fibrosis

Tsuchiya, Y., Seki, T., Kobayashi, K., Komazawa‐Sakon, S., Shichino, S., Nishina, T., Fukuhara, K., Ikejima, K., Nagai, H., Igarashi, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42058-z · Cited by 55 · see citing works

Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice.

Liu, X., Zhang, P., Martin, R. C. G., Cui, G., Wang, G., Tan, Y., Cai, L., Lv, G., & Li, Y. (2016) · PubMed Central · Cited by 50 · see citing works

Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease

Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 50 · see citing works

Novel Therapeutic Targets in Liver Fibrosis

Zhang, J., Liu, Q., He, J., & Li, Y. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.766855 · Cited by 46 · see citing works

Implications of Mitochondrial Unfolded Protein Response and Mitokines: A Perspective on Fatty Liver Diseases

Yi, H. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.1.39 · Cited by 44 · see citing works

A review of fibroblast growth factor 21 in diabetic cardiomyopathy

Zhang, X., Luo, Y., Xu, X., Tang, F., Yi, P., Qiu, B., & Hao, Y. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09809-x · Cited by 38 · see citing works

Syndecan-1 inhibits early stages of liver fibrogenesis by interfering with TGFβ1 action and upregulating MMP14

Regős, E., Abdelfattah, H. H., Reszegi, A., Szilák, L., Werling, K., Szabó, G., Kiss, A., Schaff, Z., Kovalszky, I., & Baghy, K. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.02.008 · Cited by 37 · see citing works

Fibroblast growth factor 18 attenuates liver fibrosis and HSCs activation via the SMO-LATS1-YAP pathway

Tong, G., Chen, X., Lee, J., Fan, J., Li, S., Zhu, K., Hu, Z., Mei, L., Sui, Y., Dong, Y., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106139 · Cited by 37 · see citing works

LY2405319, an analog of fibroblast growth factor 21 ameliorates α-smooth muscle actin production through inhibition of the succinate—G-protein couple receptor 91 (GPR91) pathway in mice

Le, C. T., Nguyen, G., Park, S. Y., Choi, D. H., & Cho, E.-H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192146 · Cited by 35 · see citing works

Fibroblast growth factor 21 ameliorates pancreatic fibrogenesis via regulating polarization of macrophages

Wang, N., Zhao, T., Li, S., Li, Y., Wang, Y., Li, D., & Wang, W. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.06.002 · Cited by 33 · see citing works

Potential therapeutic strategies for MASH: from preclinical to clinical development

Xie, Z., Li, Y., Cheng, L., Huang, Y., Rao, W., Shi, H., & Li, J. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae029 · Cited by 31 · see citing works

Relationship of fibroblast growth factor 21 levels with inflammation, lipoproteins and non-alcoholic fatty liver disease

Tucker, B., McClelland, R. L., Allison, M., Budoff, M. J., Wu, B. J., Barter, P. J., Rye, K., & Ong, K. L. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.03.009 · Cited by 29 · see citing works

Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis

Yang, B., Lu, L., Zhou, D., Fan, W., Barbier‐Torres, L., Steggerda, J. A., Yang, H., & Yang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1007944 · Cited by 29 · see citing works

Non-Alcoholic Fatty Liver Disease in HIV/HBV Patients – a Metabolic Imbalance Aggravated by Antiretroviral Therapy and Perpetuated by the Hepatokine/Adipokine Axis Breakdown

Iacob, S. A., & Iacob, D. G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.814209 · Cited by 28 · see citing works

Fibroblast growth factor 21 ameliorates high glucose-induced fibrogenesis in mesangial cells through inhibiting STAT5 signaling pathway

Li, S., Guo, X., Zhang, T., Wang, N., Li, J., Xu, P., Zhang, S., Ren, G., & Li, D. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.06.100 · Cited by 28 · see citing works

Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management

Rinella, M. E., & Sookoian, S. C. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01187-8 · Cited by 29 · see citing works

FGF21 ameliorates hepatic fibrosis by multiple mechanisms

Meng, F., Khoso, M. H., Kang, K., He, Q., Cao, Y., Jiang, X., Xiao, W. L., & Li, D. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06707-0 · Cited by 26 · see citing works

Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)

Puengel, T., & Tacke, F. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2230115 · Cited by 24 · see citing works

Myostatin regulates energy homeostasis through autocrine- and paracrine-mediated microenvironment communication

Wang, H., Guo, S., Gao, H., Ding, J., Li, H., Kong, X., Zhang, S., He, M., Feng, Y., Wu, W., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178303 · Cited by 22 · see citing works

Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPARα/FGF21 Axis

Qiu, H., Song, E., Hu, Y., Li, T., Ku, K. C., Wang, C., Cheung, B. M. Y., Cheong, L. Y., Wang, Q., Wu, X., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.07.012 · Cited by 22 · see citing works

Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis

Nielsen, M. H., Gillum, M. P., Vrang, N., Jelsing, J., Hansen, H. H., Feigh, M., & Oró, D. (2023) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00157.2022 · Cited by 20 · see citing works

Consumption of Wild Rice (Zizania latifolia) Prevents Metabolic Associated Fatty Liver Disease through the Modulation of the Gut Microbiota in Mice Model

Hou, X., Yan, N., Du, Y., Liang, H., Zhang, Z., & Yuan, X.-L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155375 · Cited by 20 · see citing works

Effects of Lespedeza Bicolor Extract on Regulation of AMPK Associated Hepatic Lipid Metabolism in Type 2 Diabetic Mice

Kim, Y., Lee, H., Kim, S. Y., & Lim, Y. (2019) · Antioxidants · doi:10.3390/antiox8120599 · Cited by 20 · see citing works

Targeting Hepatic Stellate Cells for the Prevention and Treatment of Liver Cirrhosis and Hepatocellular Carcinoma: Strategies and Clinical Translation

Xiong, H., & Guo, J. (2025) · Pharmaceuticals · doi:10.3390/ph18040507 · Cited by 20 · see citing works

Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study.

Xue, M., Wu, Y., Zhu, B., Zou, X., Fan, W., & Li, J. (2021) · PubMed Central · Cited by 18 · see citing works

Spontaneous Browning of White Adipose Tissue Improves Angiogenesis and Reduces Macrophage Infiltration After Fat Grafting in Mice

Lin, J., Zhu, S., Liao, Y., Liang, Z., Quan, Y., He, Y., Cai, J., & Lu, F. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.845158 · Cited by 15 · see citing works

Chlorhexidine-containing chewing gum. Clinical documentation

Imfeld, T. N. (2006) · PubMed · doi:10.5167/uzh-2549 · Cited by 15 · see citing works

Fibroblast growth factor 21 alleviates unilateral ureteral obstruction-induced renal fibrosis by inhibiting Wnt/β-catenin signaling pathway.

Zhong, W., Jiang, Y., Wang, H., Luo, X., Zeng, T., Huang, H., Xiao, L., Jia, N., & Li, A. (2023) · Biochimica et biophysica acta. Molecular cell research · doi:10.1016/j.bbamcr.2023.119620 · Cited by 12 · see citing works

FGF21 Signaling Exerts Antifibrotic Properties during Pulmonary Fibrosis

Ghanem, M., Archer, G., Justet, A., Jaillet, M., Vasarmidi, E., Mordant, P., Castier, Y., Mal, H., Cazes, A., Poté, N., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202311-2021oc · Cited by 14 · see citing works

Fibroblast Growth Factor–21 ameliorates hepatic encephalopathy by activating the STAT3-SOCS3 pathway to inhibit activated hepatic stellate cells

Opoku, Y. K., Liu, Z., Afrifa, J., Kumi, A. K., Liu, H., Ghartey‐Kwansah, G., Koranteng, H., Jiang, X., Ren, G., & Li, D. (2020) · EXCLI journal · doi:10.17179/excli2020-1287 · Cited by 14 · see citing works

Fibroblast growth factor-21 as a novel metabolic factor for regulating thrombotic homeostasis

Li, S., Jia, H., Liu, Z., Wang, N., Guo, X., Cao, M., Fang, F., Yang, J., Li, J., He, Q., et al. (2022) · Scientific Reports · doi:10.1038/s41598-021-00906-2 · Cited by 14 · see citing works

TERT assists GDF11 to rejuvenate senescent VEGFR2+/CD133+ cells in elderly patients with myocardial infarction

Zhao, L., Zhang, S., Cui, J., Huang, W., Wang, J., Feng, S., Chen, N., & Gong, Q. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0290-1 · Cited by 13 · see citing works

Increased serum chemerin level to predict early onset of aortic valve stenosis

Lurins, J., Lūriņa, D., Tretjakovs, P., Mackēvičs, V., Lejnieks, A., Rapisarda, V., & Baylon, V. (2017) · Biomedical Reports · doi:10.3892/br.2017.1010 · Cited by 12 · see citing works

Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH)

Kim, K., & Kim, K. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072296 · Cited by 13 · see citing works

The endocrine FGFs axis: A systemic anti-fibrotic response that could prevent pulmonary fibrogenesis?

Ghanem, M., Archer, G., Crestani, B., & Mailleux, A. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108669 · Cited by 11 · see citing works

Epalrestat Stimulated Oxidative Stress, Inflammation, and Fibrogenesis in Mouse Liver

Le, Y., Chen, L., Zhang, Y., Bu, P., Dai, G., & Cheng, X. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx038 · Cited by 11 · see citing works

Maladaptive regeneration and metabolic dysfunction associated steatotic liver disease: Common mechanisms and potential therapeutic targets

Wu, D., & van de Graaf, S. F. J. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116437 · Cited by 10 · see citing works

FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data

Boutari, C., Triantafyllou, A., Papalavrentios, L., Goulis, I., & Sinakos, E. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128374854250709050425 · Cited by 10 · see citing works

Therapeutic Role of Fibroblast Growth Factor 21 (FGF21) in the Amelioration of Chronic Diseases

Opoku, Y. K., Liu, Z., Afrifa, J., Khoso, M. H., Ren, G., & Li, D. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09820-8 · Cited by 10 · see citing works

A study of the circulating fibroblast growth factor 21 as a novel noninvasive biomarker of hepatic injury in genotype-4 chronic hepatitis C: Egyptian patients and their response to direct-acting antiviral agents

Sagheer, G. E., Ahmad, A., Abd-ElFattah, A., Saad, Z. M., & Hamdi, L. (2018) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s173484 · Cited by 9 · see citing works

A comparative genomic study across 396 liver biopsies provides deep insight into FGF21 mode of action as a therapeutic agent in metabolic dysfunction‐associated steatotic liver disease

Tang, S., & Borlak, J. T. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70218 · Cited by 8 · see citing works

The role of ubiquitination and deubiquitination in the pathogenesis of non-alcoholic fatty liver disease

Zhang, L., Liu, S., Zhao, Q., Liu, X., Zhang, Q., Liu, M., & Zhao, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1535362 · Cited by 9 · see citing works

Prepregnancy GLP ‐ 1RA use improves maternal lipid metabolism via liver‐secreted FGF21 during pregnancy in HFD ‐fed dams

Guo, H., Jing, Y., Zhang, Y., Song, L., Wu, W., Wang, J., Wang, M., Niu, X., Wang, M., Pan, X., et al. (2025) · Obesity · doi:10.1002/oby.24328 · Cited by 8 · see citing works

CREBH knockout accelerates hepatic fibrosis in mouse models of diet-induced nonalcoholic fatty liver disease

Li, G., Zhang, J., Jiang, Q., Liu, B., & Xu, K. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117795 · Cited by 8 · see citing works

Diosmin and Hesperidin Have a Protective Effect in Diabetic Neuropathy via the FGF21 and Galectin-3 Pathway

Gölboyu, B. E., Erdoğan, M. A., Çoşar, M. A., Balıkoğlu, E., & Erbaş, O. (2024) · Medicina · doi:10.3390/medicina60101580 · Cited by 7 · see citing works

Research Progress of Fibroblast Growth Factor 21 in Fibrotic Diseases

Jia, M.-Q., Guan, C., Tao, J., & Zhou, Y. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5042762 · Cited by 7 · see citing works

Therapeutic effects of FGF21 mimetic bFKB1 on MASH and atherosclerosis in Ldlr−/−.Leiden mice

Inia, J. A., Attema, J., de Ruiter, C., Menke, A. L., Caspers, M. P. M., Verschuren, L., Wilson, M. E., Arlantico, A., Brightbill, H. D., Jukema, J. W., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202401397r · Cited by 5 · see citing works

Regulatory Networks, Management Approaches, and Emerging Treatments of Nonalcoholic Fatty Liver Disease

Yang, B., Yang, X., Tan, X., Lu, L., Fan, W., Barbier‐Torres, L., Steggerda, J. A., Liu, T., & Yang, H. (2022) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2022/6799414 · Cited by 7 · see citing works

Imperfect repair in aging: senescent cells and the hepatic fibrotic niche

Kim, J., Kim, M., & Kim, C. (2026) · BMB Reports · doi:10.5483/bmbrep.2025-0224 · Cited by 6 · see citing works

Fibroblast Growth Factor 21: Mechanisms, Therapeutic Potential, and Clinical Translation in Metabolic Dysfunction

Rama, K., Jahagirdar, V., & Sanyal, A. J. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s560034 · Cited by 6 · see citing works

Effects of metformin on parasitological, pathological changes in the brain and liver and immunological aspects during visceral toxocariasis in mice

Salama, A. M., Elmahy, R. A., Ibrahim, H. A., Amer, A. I. M., Eltantawy, A. F., & Elgendy, D. I. (2023) · Parasitology Research · doi:10.1007/s00436-023-08011-1 · Cited by 6 · see citing works

Pemafibrate ameliorates renal injury through induction of FGF21 and ketone body production in male mice

Takahara, K., Ouchi, N., Takikawa, T., Ozaki, Y., Fang, L., Kawanishi, H., Tatsumi, M., Yura, Y., Kato, K., Takefuji, M., et al. (2025) · Physiological Reports · doi:10.14814/phy2.70135 · Cited by 3 · see citing works

Senkyunolide A alleviates asthma by inhibiting TGF-β/Smad2/3 signaling pathway and NLRP3 inflammasome activation

Zhang, M., Wang, C., Zhao, R., & Yuan, J. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152809 · Cited by 3 · see citing works

Alleviative effects of fibroblast growth factor 21 on fibrogenic genes expression in the fructose activated hepatic stellate cells, an in vitro study

Shakerian, E., Yaghooti, H., Kheirollah, A., & Mohammadtaghvaei, N. (2022) · Immunopathologia Persa · doi:10.34172/ipp.2022.29268 · Cited by 3 · see citing works

Evaluation of prevention and treatment effects of fibroblast growth factor-21 in BLM-induced pulmonary fibrosis

Wang, X., Li, S., Liu, J., Sun, W., Zhao, H. Q., Han, Q., Liu, Y., Cao, X., Li, Q., Jin, Y., et al. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02540-3 · Cited by 3 · see citing works

Hepatic FGF21 Deletion Improves Glucose Metabolism, Alters Lipogenic and Chrna4 Gene Expression, and Enhances Telomere Maintenance in Aged Female Mice

Torres-Oteros, D., Nicola-Llorente, M., Sanz-Lamora, H., Pérez-Martí, A., Marrero, P., Canudas, S., Haro, D., & Relat, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010194 · Cited by 2 · see citing works

FGF21 and its Relationship with Inflammatory and Metabolic Parameters in HIV Patients after Antiretroviral Treatment

Ruiz-Padilla, A. J., Ruíz‐Noa, Y., Ibarra‐Reynoso, L. D. R., Lazo-de-la-Vega-Monroy, M.-L., Alonso‐Castro, Á. J., Sánchez-Barajas, M., Alvarez-Alvarez, R. M., & Preciado‐Puga, M. D. C. (2020) · Current HIV Research · doi:10.2174/1570162x18666200719235625 · Cited by 2 · see citing works

FGF21 Attenuates Neurodegeneration though Modulating Neuroinflammation and Oxidant-stressPreprint

Kang, K., Xu, P., Wang, M., Chunyu, J., Sun, X., Ren, G., Xiao, W. L., & li, D. (2020) · doi:10.21203/rs.2.17629/v2 · Cited by 2 · see citing works

Safety and Efficacy of FGF21 Analogues in Nonalcoholic Steatohepatitis: A Meta-Analysis of Randomized Clinical Trials

Sobral, M. V. S., Faria, H. S., Bendaham, L. C. A. R., Masiero, B. B., Gouvêa, C. A., Faria, G. D. S., dos Santos, M. D., Peres, C. D. A. P., de Oliveira, L. M., & Souto, E. B. (2025) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001868

Unlocking the potential of FGF21: a promising approach to targeting pulmonary fibrosis

Sundar, I. K. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202412-2511le

Hepatokines and polycystic ovary syndrome: investigating the connection between the hepato-ovarian axis and disorders in glycolipid metabolism in PCOS: a narrative review

Zhu, R. Y., Wang, X., Ma, J., Shi, X., Zhang, Y., Jin, J., & Zhou, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1598164

Efficacy and safety of efruxifermin for patients with NASH/MASH: an updated systematic review and meta-analysis

Xiao, Y.-J., Liu, X.-P., Zhang, Y.-L., Cheng, Y., Tian, X., Liu, Y.-Q., Deng, C.-L., & Sun, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1731065

Rôle des FGFs endocrines et leurs récepteurs au cours de la fibrose pulmonaire idiopathique

Ghanem, M. (2023) · theses.fr (ABES) · doi:10.70675/fd0d64f8zacf4z4856z9b1az66d4df37a332

Drug Development for MASH ‐Related Compensated Cirrhosis: Past, Present and Future

Zeng, R., Shao, Y. C., Lin, R.-T., Shen, X.-T., Sun, Q., Xin, X., Liu, P., Fan, J., Hu, Y., & Feng, Q. (2026) · Liver International · doi:10.1111/liv.70784

Fibroblast growth factor 21 in metabolic dysfunction-associated steatotic liver disease and beyond: from bench to bedside

Leung, H.-K., Tan, G.-J., Wong, W., Khamis, F., Zain, S. M., & Chan, W. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.20

Adipose Tissue Browning in MASLD and Its Molecular Mechanisms and Metabolic Crosstalk

Guerrero, J. J. G., del Rosario, M. A. S., Encarnacion, P. C., Lin, C.-S., Chuang, L., Notarte, K. I., Zhou, J., Wang, C., Chang, C.-W., & Li, W. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00746-z

Key Hepatokines Linking MASLD and Type 2 Diabetes: From Pathophysiological Mechanisms to Therapeutic Modulation

Foia, L. G., Goriuc, A., Luchian, I. A., Budală, D. G., Toma, V., Bogdán, M., Minea, B., & Ghemiș, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177917

Neue Therapieansätze bei MASH: Mechanismen und klinisches Potenzial

Barton, A., & Schattenberg, J. M. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2894-7716

Research Advances in the FGFR Signaling Axis in Hepatic Fibrosis

万, 良. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.16103343

Biological functions and emerging interplay of FGF21 and GDF15 in metabolic diseases and aging

Salmón‐Gómez, L., Keipert, S., Catalán, V., Rodrı́guez, A., Becerril, S., Frühbeck, G., & Gómez‐Ambrosi, J. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00627-w

Alleviative effects of fibroblast growth factor 21 on fibrogenic genes expression in the fructose activated hepatic stellate cells, an in vitro study

Shakerian, E., Yaghooti, H., Kheirollah, A., & Mohammadtaghvaei, N. (2022) · Immunopathologia Persa · doi:10.34172/ipp.2022.29268 · Cited by 3 · see citing works

FGF21 ameliorates hepatic fibrosis by multiple mechanisms

Meng, F., Khoso, M. H., Kang, K., He, Q., Cao, Y., Jiang, X., Xiao, W. L., & Li, D. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06707-0 · Cited by 26 · see citing works

Effect of fibroblast growth factor 21 on hepatic fibrosis in mice and its mechanism

DaXiu, W., & Han, J. (2018) · doi:10.3969/j.issn.1001-5256.2018.06.017

Fibroblast Growth Factor 21 Reduces Cholesterol-Induced Hepatic Fibrogenesis by Inhibiting TGF-β/Smad3C Signaling Pathway in LX2 Cells

Afarin, R., Babaahmadi‐Rezaei, H., Yaghooti, H., & Mohammadtaghvaei, N. (2021) · Hepatitis Monthly · doi:10.5812/hepatmon.113321 · Cited by 7 · see citing works

3,3′‐Diindolylmethane ameliorates experimental hepatic fibrosis via inhibiting miR ‐21 expression

Zhang, Z., Gao, Z., Hu, W., Yin, S., Wang, C., Zang, Y., Chen, J., Zhang, J., & Dong, L. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12323 · Cited by 38 · see citing works